Similar benefits of 5-years simvastatin therapy among high cardiovascular risk patients, independently of baseline C-reactive protein concentration – The Heart Protection Study Discussion
Article Sidebar
Main Article Content
Abstract
The article presents the vascular effects of 5-years statin therapy according to the different baseline concentrations of C-reactive protein and LDL cholesterol. To the Heart Protection Study, 20 536 patients aged 40–80 years at high cardiovascular risk, hospitalized in United Kingdom between 1994–1997 were involved.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Després J.P.: CRP: Star trekking the galaxy of risk markers. Lancet 2011, 377: 441-442 [DOI:10.1016/S0140-6736(10)62316-1].
3. Choudhry N.K., Patrick A.R., Glynn R.J., Avorn J.: The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels. J. Am. Coll. Cardiol. 2011, 57: 784-791.